当前位置: 首页 >> 检索结果
181. Lifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.
作者: Tomas Vetrovsky.;Michal Siranec.;Tereza Frybova.;Iulian Gant.;Iveta Svobodova.;Ales Linhart.;Jiri Parenica.;Marie Miklikova.;Lenka Sujakova.;David Pospisil.;Radek Pelouch.;Daniela Odrazkova.;Petr Parizek.;Jan Precek.;Martin Hutyra.;Milos Taborsky.;Jiri Vesely.;Martin Griva.;Miroslav Semerad.;Vaclav Bunc.;Karolina Hrabcova.;Adela Vojkuvkova.;Michal Svoboda.;Jan Belohlavek.; .
来源: Circulation. 2024年149卷3期177-188页
Physical activity is pivotal in managing heart failure with reduced ejection fraction, and walking integrated into daily life is an especially suitable form of physical activity. This study aimed to determine whether a 6-month lifestyle walking intervention combining self-monitoring and regular telephone counseling improves functional capacity assessed by the 6-minute walk test (6MWT) in patients with stable heart failure with reduced ejection fraction compared with usual care.
182. Efficacy and User Experience of a Novel X-Ray Shield on Operator Radiation Exposure During Cardiac Catheterization: A Randomized Controlled Trial.
作者: Cedric Davidsen.;Kristian Ytre-Hauge.;Andreas Tefre Samnøy.;Kjell Vikenes.;Patrizio Lancellotti.;Vegard Tuseth.
来源: Circ Cardiovasc Interv. 2023年16卷12期e013199页
Radiation shielding is mandatory during cardiac catheterization, but there is a need to improve efficacy and ease of use.
183. Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Substudy.
作者: Jamie Kitt.;Samuel Krasner.;Logan Barr.;Annabelle Frost.;Katherine Tucker.;Paul A Bateman.;Katie Suriano.;Yvonne Kenworthy.;Winok Lapidaire.;Miriam Lacharie.;Rebecca Mills.;Cristian Roman.;Lucy Mackillop.;Alexandra Cairns.;Christina Aye.;Vanessa Ferreira.;Stefan Piechnik.;Elena Lukaschuk.;Basky Thilaganathan.;Lucy C Chappell.;Adam J Lewandowski.;Richard J McManus.;Paul Leeson.
来源: Circulation. 2024年149卷7期529-541页
Hypertensive pregnancy disorders are associated with adverse cardiac remodeling, which can fail to reverse in the postpartum period in some women. The Physician-Optimized Postpartum Hypertension Treatment trial demonstrated that improved blood pressure control while the cardiovascular system recovers postpartum associates with persistently reduced blood pressure. We now report the effect on cardiac remodeling.
184. Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201).
作者: A John Camm.;Jonathan P Piccini.;Marco Alings.;Paul Dorian.;Gilbert Gosselin.;Marie-Claude Guertin.;James E Ip.;Peter R Kowey.;Blandine Mondésert.;Fransisco J Prins.;Jean-Francois Roux.;Bruce S Stambler.;Jwm van Eck.;Nadea Al Windy.;Nathalie Thermil.;Silvia Shardonofsky.;David B Bharucha.;Denis Roy.
来源: Circ Arrhythm Electrophysiol. 2023年16卷12期639-650页
Despite chronic therapies, atrial fibrillation (AF) leads to rapid ventricular rates (RVR) often requiring intravenous treatments. Etripamil is a fast-acting, calcium-channel blocker administered intranasally affecting the atrioventricular node within minutes.
185. Economic Modeling Analysis of an Intensive GDMT Optimization Program in Hospitalized Heart Failure Patients.
作者: Neal M Dixit.;Neil U Parikh.;Boback Ziaeian.;Gregg C Fonarow.
来源: Circ Heart Fail. 2023年16卷12期e011218页
The STRONG-HF trial (Safety, Tolerability and Efficacy of Up-Titration of Guideline-Directed Medical Therapies for Acute Heart Failure) demonstrated substantial reductions in the composite of mortality and morbidity over 6 months among hospitalized patients with heart failure (HF) who were randomized to intensive guideline-directed medical therapy (GDMT) optimization compared with usual care. Whether an intensive GDMT optimization program would be cost-effective for patients with HF with reduced ejection fraction is unknown.
186. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction: Cost-Effectiveness Analysis of the REVIVED-BCIS2 Trial.
作者: Carlos Chivardi.;Holly Morgan.;Mark J Sculpher.;Tim Clayton.;Richard Evans.;Matthew Dodd.;Mark Petrie.;Christopher A Rinaldi.;Peter O'Kane.;Louise Brown.;Divaka Perera.;Pedro Saramago.; .
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷1期e010533页
Percutaneous coronary intervention (PCI) is frequently undertaken in patients with ischemic left ventricular systolic dysfunction. The REVIVED (Revascularization for Ischemic Ventricular Dysfunction)-BCIS2 (British Cardiovascular Society-2) trial concluded that PCI did not reduce the incidence of all-cause death or heart failure hospitalization; however, patients assigned to PCI reported better initial health-related quality of life than those assigned to optimal medical therapy (OMT) alone. The aim of this study was to assess the cost-effectiveness of PCI+OMT compared with OMT alone.
187. No Effect of Continued Antiarrhythmic Drug Treatment on Top of Optimized Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation: Results From the POWDER-AF2 Trial.
作者: Anthony Demolder.;Louisa O'Neill.;Milad El Haddad.;Daniel Scherr.;Johan Vijgen.;Michael Wolf.;Benjamin Berte.;Felipe Bisbal.;Arne Johannessen.;Maximo Rivero-Ayerza.;Tom De Potter.;Benjamin De Becker.;Jean-Benoît le Polain de Waroux.;Sebastien Knecht.;Rene Tavernier.;Mattias Duytschaever.
来源: Circ Arrhythm Electrophysiol. 2023年16卷11期e012043页
In patients with persistent atrial fibrillation (PersAF), catheter ablation aiming for pulmonary vein isolation (PVI) is associated with moderate clinical effectiveness. We investigated the benefit of continuing previously ineffective class 1C or 3 antiarrhythmic drug therapy (ADT) in the setting of a standardized PVI-only ablation strategy.
188. ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial.
作者: Aish Sinha.;Haseeb Rahman.;Abdel Douiri.;Ozan M Demir.;Kalpa De Silva.;Brian Clapp.;Ian Webb.;Ankur Gulati.;Pedro Pinho.;Utkarsh Dutta.;Howard Ellis.;Ajay M Shah.;Amedeo Chiribiri.;Michael Marber.;Andrew J Webb.;Divaka Perera.
来源: Circulation. 2024年149卷1期36-47页
Angina with nonobstructive coronary arteries is a common condition for which no effective treatment has been established. We hypothesized that the measurement of coronary flow reserve (CFR) allows identification of patients with angina with nonobstructive coronary arteries who would benefit from anti-ischemic therapy.
189. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.
作者: Michel Azizi.;Andrew S P Sharp.;Naomi D L Fisher.;Michael A Weber.;Melvin D Lobo.;Joost Daemen.;Philipp Lurz.;Felix Mahfoud.;Roland E Schmieder.;Jan Basile.;Michael J Bloch.;Manish Saxena.;Yale Wang.;Kintur Sanghvi.;J Stephen Jenkins.;Chandan Devireddy.;Florian Rader.;Philippe Gosse.;Lisa Claude.;Dimitri A Augustin.;Candace K McClure.;Ajay J Kirtane.; .
来源: Circulation. 2024年149卷10期747-759页
The randomized, sham-controlled RADIANCE-HTN (A Study of the Recor Medical Paradise System in Clinical Hypertension) SOLO, RADIANCE-HTN TRIO, and RADIANCE II (A Study of the Recor Medical Paradise System in Stage II Hypertension) trials independently met their primary end point of a greater reduction in daytime ambulatory systolic blood pressure (SBP) 2 months after ultrasound renal denervation (uRDN) in patients with hypertension. To characterize the longer-term effectiveness and safety of uRDN versus sham at 6 months, after the blinded addition of antihypertensive treatments (AHTs), we pooled individual patient data across these 3 similarly designed trials.
190. Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial.
作者: Josep Rodés-Cabau.;Henrique Barbosa Ribeiro.;Siamak Mohammadi.;Vicenç Serra.;Talal Al-Atassi.;Andres Iñiguez.;Victoria Vilalta.;Luis Nombela-Franco.;José Ignacio Sáez de Ibarra Sánchez.;Vincent Auffret.;Jessica Forcillo.;Lenard Conradi.;Marina Urena.;Cesar Moris.;Antonio Muñoz-Garcia.;Jean-Michel Paradis.;Eric Dumont.;Dimitri Kalavrouziotis.;Pablo Maria Pomerantzeff.;Vitor Emer Egypto Rosa.;Mariana Pezzute Lopes.;Carles Sureda.;Victor Alfonso Jimenez Diaz.;Carlos Giuliani.;Marisa Avvedimento.;Emilie Pelletier-Beaumont.;Philippe Pibarot.; .
来源: Circulation. 2024年149卷9期644-655页
The optimal treatment in patients with severe aortic stenosis and small aortic annulus (SAA) remains to be determined. This study aimed to compare the hemodynamic and clinical outcomes between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with a SAA.
191. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.
作者: Sung-Jin Hong.;Seung-Jun Lee.;Yongsung Suh.;Kyeong Ho Yun.;Tae Soo Kang.;Sanghoon Shin.;Sung Woo Kwon.;Jun-Won Lee.;Deok-Kyu Cho.;Jong-Kwan Park.;Jang-Whan Bae.;Woong Cheol Kang.;Seunghwan Kim.;Yong-Joon Lee.;Chul-Min Ahn.;Jung-Sun Kim.;Byeong-Keuk Kim.;Young-Guk Ko.;Donghoon Choi.;Yangsoo Jang.;Myeong-Ki Hong.; .
来源: Circulation. 2024年149卷8期562-573页
Stopping aspirin within 1 month after implantation of a drug-eluting stent for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome. The aim of this study was to investigate whether ticagrelor monotherapy after <1 month of dual antiplatelet therapy (DAPT) is noninferior to 12 months of ticagrelor-based DAPT for adverse cardiovascular and bleeding events in patients with acute coronary syndrome.
192. One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: A Prespecified Analysis of the SWISS-APERO Randomized Clinical Trial.
作者: Roberto Galea.;Nicolas Meneveau.;Federico De Marco.;Adel Aminian.;Dik Heg.;Konstantina Chalkou.;Christoph Gräni.;Frederic Anselme.;Anna Franzone.;Pascal Vranckx.;Urs Fischer.;Francesco Bedogni.;Lorenz Räber.;Marco Valgimigli.
来源: Circulation. 2024年149卷6期484-486页 193. Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation.
作者: Samir R Kapadia.;Amar Krishnaswamy.;Brian Whisenant.;Srinivasa Potluri.;Vijay Iyer.;Joseph Aragon.;Philip Gideon.;Justin Strote.;Robert Leonardi.;Himanshu Agarwal.;German Larrain.;Carlos Sanchez.;Sidakpal S Panaich.;James Harvey.;Torsten Vahl.;Venu Menon.;Kathy Wolski.;Qiuqing Wang.;Martin B Leon.
来源: Circulation. 2024年149卷10期734-743页
Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) and is associated with increased risk of bleeding and stroke. While left atrial appendage occlusion (LAAO) is approved as an alternative to anticoagulants for stroke prevention in patients with AF, placement of these devices in patients with severe aortic stenosis, or when performed at the same time as TAVR, has not been extensively studied.
194. Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF.
作者: Gregory D Lewis.;Kensey Gosch.;Laura P Cohen.;Michael E Nassif.;Sheryl L Windsor.;Barry A Borlaug.;Dalane W Kitzman.;Sanjiv J Shah.;Taiyeb Khumri.;Guillermo Umpierrez.;Sumant Lamba.;Kavita Sharma.;Sadiya S Khan.;Mikhail N Kosiborod.;Andrew J Sauer.
来源: Circ Heart Fail. 2023年16卷11期e010633页
Heart failure with preserved ejection fraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive. We sought to explore the association between prespecified patient characteristics and changes in 6-minute walk distance that constitute a clinically significant response to dapagliflozin.
195. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
作者: Jennifer Rymer.;Sonia S Anand.;E Sebastian Debus.;Lloyd P Haskell.;Connie N Hess.;W Schuyler Jones.;Eva Muehlhofer.;Scott D Berkowitz.;Rupert M Bauersachs.;Marc P Bonaca.;Manesh R Patel.
来源: Circulation. 2023年148卷24期1919-1928页
Rivaroxaban plus aspirin compared with aspirin alone reduced major cardiac and ischemic limb events after lower extremity revascularization (LER) in the VOYAGER PAD (Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) trial. The effect has not been described in patients undergoing endovascular LER.
196. Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial.
作者: Min Chul Kim.;Yongwhan Lim.;Seung Hun Lee.;Yoonmin Shin.;Joon Ho Ahn.;Dae Young Hyun.;Kyung Hoon Cho.;Doo Sun Sim.;Young Joon Hong.;Ju Han Kim.;Myung Ho Jeong.;Yong Hun Jung.;In-Seok Jeong.;Youngkeun Ahn.
来源: Circulation. 2023年148卷20期1570-1581页
Although venoarterial extracorporeal membrane oxygenation (VA-ECMO) is beneficial for the treatment of profound cardiogenic shock, peripheral VA-ECMO cannulation can increase left ventricular afterload, thus compromising myocardial recovery. We investigated whether early routine left ventricular unloading can reduce 30-day mortality compared with the conventional approach in patients with cardiogenic shock undergoing VA-ECMO.
197. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
作者: Frederick Raal.;Ronen Durst.;Ran Bi.;Zsolt Talloczy.;Pierre Maheux.;Anastasia Lesogor.;John J P Kastelein.; .
来源: Circulation. 2024年149卷5期354-362页
Homozygous familial hypercholesterolemia is a genetic disease characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) and a high risk of premature cardiovascular events. The proof-of-concept study ORION-2 (A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia) showed that inclisiran, a small interfering RNA that prevents production of the hepatic PCSK9 protein (proprotein convertase subtilisin/kexin type 9), could lead to durable reductions in LDL-C levels when added to statins and ezetimibe in patients with homozygous familial hypercholesterolemia.
198. Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.
作者: Denis J Wakeham.;Erika Ivey.;Sophie A Saland.;Joshua S Lewis.;Dean Palmer.;Margot Morris.;Jeffery L Bleich.;Peter G Weyand.;Tiffany L Brazile.;Christopher M Hearon.;Satyam Sarma.;James P MacNamara.;Michinari Hieda.;Benjamin D Levine.
来源: Circulation. 2023年148卷25期2008-2016页
Despite advances in medical and cardiac resynchronization therapy (CRT), individuals with chronic congestive heart failure (CHF) have persistent symptoms, including exercise intolerance. Optimizing cardio-locomotor coupling may increase stroke volume and skeletal muscle perfusion as previously shown in healthy runners. Therefore, we tested the hypothesis that exercise stroke volume and cardiac output would be higher during fixed-paced walking when steps were synchronized with the diastolic compared with systolic portion of the cardiac cycle in patients with CHF and CRT.
199. Longitudinal Follow-Up of Children With HLHS and Association Between Norwood Shunt Type and Long-Term Outcomes: The SVR III Study.
作者: Caren S Goldberg.;Felicia Trachtenberg.;J William Gaynor.;William T Mahle.;Chitra Ravishankar.;Steven M Schwartz.;James F Cnota.;Richard G Ohye.;Russell Gongwer.;Michael Taylor.;Stephen Paridon.;Peter C Frommelt.;Katherine Afton.;Andrew M Atz.;Kristin M Burns.;Jon A Detterich.;Kevin D Hill.;Antonio G Cabrera.;Alan B Lewis.;Christian Pizarro.;Amee Shah.;Binu Sharma.;Jane W Newburger.; .
来源: Circulation. 2023年148卷17期1330-1339页
In the SVR trial (Single Ventricle Reconstruction), newborns with hypoplastic left heart syndrome were randomly assigned to receive a modified Blalock-Taussig-Thomas shunt (mBTTS) or a right ventricle-to-pulmonary artery shunt (RVPAS) at Norwood operation. Transplant-free survival was superior in the RVPAS group at 1 year, but no longer differed by treatment group at 6 years; both treatment groups had accumulated important morbidities. In the third follow-up of this cohort (SVRIII [Long-Term Outcomes of Children With Hypoplastic Left Heart Syndrome and the Impact of Norwood Shunt Type]), we measured longitudinal outcomes and their risk factors through 12 years of age.
200. Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial.
作者: Novalia P Sidik.;Bethany Stanley.;Robert Sykes.;Andrew J Morrow.;Conor P Bradley.;Michael McDermott.;Thomas J Ford.;Giles Roditi.;Allister Hargreaves.;David Stobo.;Jacqueline Adams.;John Byrne.;Ahmed Mahrous.;Robin Young.;David Carrick.;Ross McGeoch.;David Corcoran.;Ninian N Lang.;Robert Heggie.;Olivia Wu.;Margaret B McEntegart.;Alex McConnachie.;Colin Berry.
来源: Circulation. 2024年149卷1期7-23页
We investigated the usefulness of invasive coronary function testing to diagnose the cause of angina in patients with no obstructive coronary arteries.
|